Literature DB >> 9326242

Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2.

R S Larson1, D C Brown, L A Sklar.   

Abstract

All-trans retinoic acid (tRA) is a potent differentiation agent that is effective therapy for acute promyelocytic leukemia (APL). However, 5% to 25% of patients develop retinoic acid syndrome, a potentially life-threatening complication in which the pathogenesis relates to adhesive alterations of APL cells. Therefore, we investigated the relationship between tRA-induced differentiation and the adhesive properties of APL cells. After confirming differentiation-related morphological changes of NB-4 cells in response to tRA, we showed that homotypic aggregation of NB-4 cells grown in tRA for 72 hours is dose-dependent with a median effective dose of approximately 50 nmol/L. Maximal aggregation occurred at mean and peak therapeutic serum concentrations (100 and 1,000 nmol/L, respectively). Aggregation also increased with the length of tRA exposure over 168 hours. Aggregation was inhibited by neutralizing antibodies against LFA-1 and ICAM-2. Notably, antibodies directed against VLA-4, other beta2 integrins (Mac-1 and p150), or other potential LFA-1 counterstructures that were expressed on the cell surface (ICAM-1 and ICAM-3) did not block aggregation. Aggregation occurred with similar kinetics regardless of the presence of phorbol ester or the "activating" monoclonal antibody (MoAb) KIM 185, suggesting that the avidity of LFA-1 is not modulated on NB-4 cells in a manner similar to other leukocytes. Consistent with the prompt clinical effectiveness of methyl prednisolone sodium succinate (MPSS) in retinoic acid syndrome, MPSS rapidly inhibited homotypic aggregation in a dose-dependent manner. Thus, tRA alters the adhesive properties of APL cells by inducing the expression of high-avidity beta2 integrins, aggregation is inhibited by LFA-1 and ICAM-2 MoAb, and tRA effects are rapidly reversible by MPSS. Taken together, our findings provide a clinically relevant system for study of LFA-1/ICAM-2 interaction and suggest a mechanism in part for retinoic acid syndrome and the effectiveness of MPSS in ameliorating retinoic acid syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326242

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Use of a SQUID array to detect T-cells with magnetic nanoparticles in determining transplant rejection.

Authors:  Edward R Flynn; H C Bryant; Christian Bergemann; Richard S Larson; Debbie Lovato; Dmitri A Sergatskov
Journal:  J Magn Magn Mater       Date:  2007-04       Impact factor: 2.993

2.  Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid.

Authors:  Pedro Horna; Ling Zhang; Eduardo M Sotomayor; Jeffrey E Lancet; Lynn C Moscinski
Journal:  Am J Clin Pathol       Date:  2014-10       Impact factor: 2.493

3.  Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment.

Authors:  E M Rego; G C De Santis
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-10-24       Impact factor: 2.576

4.  Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Authors:  Anna Falanga; Laura Russo; Carmen J Tartari
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-21       Impact factor: 2.576

5.  The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature.

Authors:  Pau Montesinos; Miguel A Sanz
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-04       Impact factor: 2.576

6.  Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era.

Authors:  Maria Pagoni; Maria Garofalaki; Fotios Panitsas; Kalliopi Manola; Katerina Psarra; Panagiotis Economopoulos; Aggeliki Vourtsi; Marios Antoniades; Kostas Gkirkas; Evangelia Tzouvara; Fotis Katis; Chrystalla Prokopiou; Irene Tziotziou; Artemis Balta; Eleni Lemissiou; Panagiotis Tsirigotis; Panagiotis Repoussis; Nicolas Harhalakis
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-28       Impact factor: 2.576

7.  Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis.

Authors:  Renata Cabral; Juan Carlos Caballero; Sara Alonso; Julio Dávila; Monica Cabrero; Dolores Caballero; Lourdes Vázquez; Fermin Sánchez-Guijo; Lucia López; Maria C Cañizo; Maria V Mateos; Marcos González
Journal:  Hematol Rep       Date:  2014-11-19

8.  HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.

Authors:  Lanlan Tang; Wenwen Chai; Fanghua Ye; Yan Yu; Lizhi Cao; Minghua Yang; Min Xie; Liangchun Yang
Journal:  Oncotarget       Date:  2017-04-18

9.  Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome.

Authors:  Luciana Yamamoto de Almeida; Diego Antonio Pereira-Martins; Ana Sílvia Gouvêa Lima; Márcia Sueli Baggio; Luisa Corrêa de Araujo Koury; Ana Paula Lange; Sarah Cristina Bassi; Priscila Santos Scheucher; Eduardo Magalhães Rego
Journal:  BMC Cancer       Date:  2020-08-28       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.